Read our Recent Headlines

October 21 Biotech Update

Clearly the sector did not turn the corner after the presidential debate even though it should have assuaged concerns over the importance of drug pricing to the candidates. The sector.

Dave Trading – October Edition – Bargain Hunting Time?

*** David Sobek is a disciplined value investor.  Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.

October 19 Biotech Update

There is really nothing to talk about today with a lack of news. I suspect we will be weak into the final debate and stretch run of the campaign. Recent.

October 18 Biotech Update

It is still not great out there for the sector but yesterday was not awful, which I guess is an improvement. Perhaps we have reached a short term bottom and.

Catatonic Economics – No one is talking about the greatest risk to America

Financial markets talk about a lot of headwinds to the economy.  China devaluation, negative S&P earnings, presidential race, central bank actions, European banking problems, Japan, oil, etc.  One that should.

October 17 Biotech Update

The sector continues to weaken but still remains above the 200 day moving average. It seems to me that some panic is starting to set in as the sector cannot.

October 14 Biotech Update

The sector may be due for a snap back (with the broader market) but I still get the sense that people are worried. My prevailing thought has been that this.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!